Soleus Capital Management’s Tango Therapeutics TNGX Stock Holding History

Soleus Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.2M	Buy	709,000 +259,000	+58%	+$6.4M	0.76%	36
2026 Q1	$9.41M	Buy	450,000 +440,000	+4,400%	+$6.12M	0.38%	52
2025 Q4	$88.6K	Sell	10,000 -290,000	-97%	-$2.5M	﹤0.01%	95
2025 Q3	$2.52M	Sell	300,000 -430,000	-59%	-$2.91M	0.13%	69
2025 Q2	$3.74M	Buy	+730,000	New	+$1.8M	0.25%	63
2024 Q4	–	Sell	-343,152	Closed	-$2.64M	–	107
2024 Q3	$2.64M	Sell	343,152 -706,743	-67%	-$6.74M	0.2%	73
2024 Q2	$9.01M	Sell	1,049,895 -300,250	-22%	-$2.32M	0.79%	41
2024 Q1	$10.7M	Buy	1,350,145 +503,000	+59%	+$5.39M	0.8%	36
2023 Q4	$8.39M	Sell	847,145 -1,081,874	-56%	-$9.39M	0.93%	34
2023 Q3	$21.7M	Buy	1,929,019 +152,122	+9%	+$928K	2%	15
2023 Q2	$5.9M	Buy	+1,776,897	New	+$6.39M	0.66%	45

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Soleus Capital Management's TNGX Position: Q2 2026 in Review

Soleus Capital Management increased its Tango Therapeutics (TNGX) stake by 58% in Q2 2026, buying an estimated $6.4M and bringing the position to 709,000 shares worth $22.2M. The position accounts for 0.76% of the portfolio, ranked #36.

Soleus Capital Management first reported a position in TNGX in Q2 2023 and has held it in 11 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Soleus Capital Management held 709,000 shares of Tango Therapeutics worth $22.2M as of Q2 2026.
Soleus Capital Management bought 259,000 Tango Therapeutics shares in Q2 2026, an estimated $6.4M.
Tango Therapeutics made up 0.76% of Soleus Capital Management's portfolio in Q2 2026, its #36 holding.
Soleus Capital Management first reported a position in Tango Therapeutics in Q2 2023 and has held it in 11 quarters since.
249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.